MedMira (MIR) Stock Overview
A biotechnology company, researches, develops, manufactures, and sells rapid diagnostics and technology platforms in North America, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
MIR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
MedMira Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.08 |
| 52 Week High | CA$0.14 |
| 52 Week Low | CA$0.06 |
| Beta | 0.54 |
| 1 Month Change | 14.29% |
| 3 Month Change | 0% |
| 1 Year Change | -5.88% |
| 3 Year Change | 33.33% |
| 5 Year Change | -64.44% |
| Change since IPO | -99.24% |
Recent News & Updates
Shareholder Returns
| MIR | CA Medical Equipment | CA Market | |
|---|---|---|---|
| 7D | 33.3% | 1.2% | -0.02% |
| 1Y | -5.9% | -20.7% | 23.0% |
Return vs Industry: MIR exceeded the Canadian Medical Equipment industry which returned -18.6% over the past year.
Return vs Market: MIR underperformed the Canadian Market which returned 23.6% over the past year.
Price Volatility
| MIR volatility | |
|---|---|
| MIR Average Weekly Movement | 11.2% |
| Medical Equipment Industry Average Movement | 10.1% |
| Market Average Movement | 10.2% |
| 10% most volatile stocks in CA Market | 20.4% |
| 10% least volatile stocks in CA Market | 3.3% |
Stable Share Price: MIR has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: MIR's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | n/a | Hermes Chan | medmira.com |
MedMira Inc., a biotechnology company, researches, develops, manufactures, and sells rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product for preliminary screening of HIV and hepatitis. It also provides the Miriad RVF toolkit, which facilitates the development and commercialization of rapid diagnostics; and Reveal G4 HIV tests.
MedMira Inc. Fundamentals Summary
| MIR fundamental statistics | |
|---|---|
| Market cap | CA$52.63m |
| Earnings (TTM) | -CA$4.52m |
| Revenue (TTM) | CA$240.51k |
Is MIR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MIR income statement (TTM) | |
|---|---|
| Revenue | CA$240.51k |
| Cost of Revenue | CA$913.21k |
| Gross Profit | -CA$672.70k |
| Other Expenses | CA$3.85m |
| Earnings | -CA$4.52m |
Last Reported Earnings
Jul 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0064 |
| Gross Margin | -279.70% |
| Net Profit Margin | -1,881.18% |
| Debt/Equity Ratio | -63.6% |
How did MIR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/16 00:20 |
| End of Day Share Price | 2025/12/16 00:00 |
| Earnings | 2025/07/31 |
| Annual Earnings | 2025/07/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MedMira Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.